{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:49:30Z","timestamp":1765828170567,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1111\/jth.15692","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T08:11:28Z","timestamp":1646640688000},"page":"1376-1384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-4143","authenticated-orcid":false,"given":"Ingrid M.","family":"Bistervels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1806-1050","authenticated-orcid":false,"given":"Roisin","family":"Bavalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Gebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthonie W.A.","family":"Lensing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1006-6420","authenticated-orcid":false,"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin H.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-9062","authenticated-orcid":false,"given":"Michiel","family":"Coppens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1111\/jth.15692_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN\u2010DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"issue":"17","key":"10.1111\/jth.15692_bb0015","first-page":"1890","article-title":"Frequency of and risk factors for preventable medication\u2010related hospital admissions in the Netherlands","volume":"168","author":"Leendertse","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.15692_bb0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-9560-12-20","article-title":"Drug\u2010drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study","volume":"12","author":"Teklay","year":"2014","journal-title":"Thromb J"},{"issue":"6 Suppl","key":"10.1111\/jth.15692_bb0025","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence\u2010based clinical practice guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"issue":"4","key":"10.1111\/jth.15692_bb0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","article-title":"Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation","volume":"133","author":"Piccini","year":"2016","journal-title":"Circulation"},{"key":"10.1111\/jth.15692_bb0035","doi-asserted-by":"crossref","first-page":"i2868","DOI":"10.1136\/bmj.i2868","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial","volume":"353","author":"Focks","year":"2016","journal-title":"Bmj\u2010Brit Med J"},{"key":"10.1111\/jth.15692_bb0040","unstructured":"Agency EM. European public assessment report for Xarelto. 2018."},{"key":"10.1111\/jth.15692_bb0045","unstructured":"Bayer PA. Xarelto\u00ae(rivaroxaban) summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\u2026. 2013."},{"issue":"26","key":"10.1111\/jth.15692_bb0050","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1111\/jth.15692_bb0055","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Investigators","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1111\/jth.15692_bb0060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non\u2010surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"suppl 3","key":"10.1111\/jth.15692_bb0065","first-page":"A12422","article-title":"Influence of polypharmacy on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE\u2010COVER\u00ae and RE\u2010COVER II\u2122 (Abstract 12422)","volume":"132","author":"Goldhaber","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1111\/jth.15692_bb0070","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In vitro and in vivo P\u2010glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1111\/jth.15692_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15692","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622001878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622001878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:34:43Z","timestamp":1761536083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622001878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1538783622001878"],"URL":"https:\/\/doi.org\/10.1111\/jth.15692","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}